Condition: Prostate Cancer · CDK12 Gene Mutation · Sponsor: Tianjin Medical University Second Hospital
The aim of this study is to evaluate the efficacy and safety of vediximab monotherapy or in combination with enrolizumab for second-line treatment of CDK12 alterations mCRPC that has failed standard therapy. The research results are expected to provide new insights and breakthroughs for the treatment of advanced prostate cancer.
This description comes directly from the study's public registry record.
Haitao Wang, Ph.D · +86-022-88326385 · peterrock2000@126.com
Jinhuan Wang, Ph.D · +86-022-88326610 · wjhhappy2008@163.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical Unversity Second Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06663007